Drospirenone
Slynd, Drovelis, Lydisilka (drospirenone) is a small molecule pharmaceutical. Drospirenone was first approved as Slynd on 2019-05-23. It has been approved in Europe to treat contraception. The pharmaceutical is active against mineralocorticoid receptor. Yasmin's patent is valid until 2031-06-28 (FDA).
| Trade Name | Drovelis, Lydisilka |
|---|---|
| Common Name | Drospirenone |
| Indication | contraception |
| Drug Class | Aldosterone antagonists (spironolactone type) |
